Previous studies made significant contributions to the field.[18] RPhs targeting receptors, particularly somatostatin receptors, have been shown to be effective in NETs.[19,20] Prostate‐specific membrane antigen (PSMA) targeting in prostate cancer and CD20 targeting in lymphomas have both yielded promising results. Here, FOLH1 is linked to prostate carcinoma.